Yuval Cohen
Yuval Cohen founded Celsus Therapeutics Plc. He is Chief Executive Officer & Director at Corbus Pharmaceuticals Holdings, Inc. and Chief Executive Officer & Director at Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.).
In the past Yuval Cohen was Director & Senior Vice President at Celsus Therapeutics Plc.
Dr. Cohen received an undergraduate degree from the University of Cape Town and a doctorate from the University of Paris V.
Transactions
Date
Transaction
Value
| 11/11/2020 | 4,240 | Acquisition at $1.21 per share. | 5,130 |
| 03/17/2020 | 4,300 | Acquisition at $3.49 per share. | 15,007 |
| 11/12/2019 | 1,430 | Acquisition at $4.26 per share. | 6,091 |
| 08/12/2019 | 1,175 | Acquisition at $6.06 per share. | 7,120 |
| 05/13/2019 | 995 | Acquisition at $6.99 per share. | 6,955 |
| 03/14/2019 | 1,530 | Acquisition at $6.49 per share. | 9,929 |
| 05/15/2018 | 1,725 | Acquisition at $5.85 per share. | 10,091 |
| 03/14/2018 | 1,160 | Acquisition at $6.88 per share. | 7,980 |
| 11/10/2017 | 1,000 | Acquisition at $7.17 per share. | 7,170 |
| 08/11/2017 | 1,695 | Acquisition at $6 per share. | 10,170 |
| 05/11/2017 | 3,250 | Acquisition at $6.01 per share. | 19,532 |
| 03/16/2017 | 20,000 | Derivative/Non-derivative trans. at $1 per share. | 20,000 |
| 11/22/2016 | 1,340 | Acquisition at $7.64 per share. | 10,237 |
| 08/17/2016 | 20,000 | Derivative/Non-derivative trans. at $1 per share. | 20,000 |
| 06/06/2016 | 1,500 | Acquisition at $3.34 per share. | 5,010 |
| 05/18/2016 | 2,125 | Acquisition at $2.4 per share. | 5,100 |
